Valamehr Bahram 4

What Happened
Valamehr Bahram, President & CEO and a director of Fate Therapeutics (FATE), disposed of 28,946 shares of common stock on May 20, 2026, for total proceeds of approximately $54,482. The reported weighted average price was $1.88 per share (range $1.825–$1.935).

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (timely filed).
• Transaction type: Sale (code S) — 28,946 shares sold for ~$54,482. Weighted average sale price noted as $1.88; prices ranged $1.825–$1.935 (filing says detailed per-price breakdown is available on request).
• Reason: Sale required to cover tax withholding on the vesting of 50,000 performance-based RSUs granted July 29, 2024 (footnote). The sale was an automatic "sell-to-cover" executed pursuant to an irrevocable election and was not at the Reporting Person’s discretion. (Footnotes F1, F2).
• Shares owned after the transaction: not specified in the provided filing.

Context
This was a routine sell-to-cover tied to RSU vesting to satisfy tax obligations, not an open discretionary sale that necessarily signals a change in insider sentiment. Such transactions are commonly required when equity awards vest and do not by themselves indicate the insider’s view on the company’s prospects.